BIRC5 and cancer: Despite T cell responses to “universal” TAAs can be detected also in patients with early stages of cancer (30, 31), no significantly higher levels of T-cells specific for TERT and Survivin were detected at baseline or at the time of diagnosis of cancer in the blood of T and NT patients.